Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxelumab
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Oxelumab is a human monoclonal antibody that targets the OX40 ligand (OX40L; also known as TNFSF4 or CD252), a member of the tumor necrosis factor superfamily. By inhibiting the interaction between OX40 and its ligand OX40L, oxelumab modulates T cell responses and has been investigated for its potential to treat immune-mediated diseases such as asthma and allergic rhinitis. The drug was developed collaboratively by Genentech, Roche, and Genmab. Oxelumab reached phase II clinical trials for allergic asthma and phase I for allergic rhinitis but development was discontinued in both indications. Preclinical studies have also explored its effects in models of ulcerative colitis[1][3][4][5][8].
- Brand names
- humab ox40l
- Other names
- oxelumabAnti-OX40L - GenentechAnti-OX-40L - GenentechAnti-OX 40L - Genentech
02
Targets
TNFSF4 (Tumor necrosis factor ligand superfamily member 4)
Beyond the preview
Go deeper on oxelumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxelumab.